Akums Receives First UK MHRA Approval for Rivaroxaban
Rivaroxaban is an oral anticoagulant prescribed for the prevention and treatment of thromboembolic disorders, including Non-Valvular Atrial Fibrillation (NVAF), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE) and clinically relevant cardiovascular risk reduction.
Pulmonary Embolism | 10/02/2026 | By News Bureau | 151
Boston Scientific will acquire Penumbra in a USD 14.5 billion cash and stock deal to expand its vascular and neurovascular portfolio, strengthening its position in thrombectomy, stroke, and cardiovascular disease treatment markets.
Pulmonary Embolism | 17/01/2026 | By News Bureau | 227
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy